114 related articles for article (PubMed ID: 21956605)
21. Determination of dabigatran in human plasma samples.
Harenberg J; Giese C; Marx S; Krämer R
Semin Thromb Hemost; 2012 Feb; 38(1):16-22. PubMed ID: 22314599
[TBL] [Abstract][Full Text] [Related]
22. Plasma dabigatran activity one week after discontinuation despite normal renal function.
Thachil J; Pike G; Keighley-Jones L; Nash MJ
Am J Med; 2013 Aug; 126(8):e5-6. PubMed ID: 23800582
[No Abstract] [Full Text] [Related]
23. Dabigatran elimination: is haemodialysis effective?
McLellan AJ; Schlaich MP
Thromb Haemost; 2013 Apr; 109(4):580-1. PubMed ID: 23389392
[No Abstract] [Full Text] [Related]
24. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial.
Eikelboom JW; Wallentin L; Connolly SJ; Ezekowitz M; Healey JS; Oldgren J; Yang S; Alings M; Kaatz S; Hohnloser SH; Diener HC; Franzosi MG; Huber K; Reilly P; Varrone J; Yusuf S
Circulation; 2011 May; 123(21):2363-72. PubMed ID: 21576658
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment.
Gschwend S; Ebert W; Schultze-Mosgau M; Breuer J
Invest Radiol; 2011 Sep; 46(9):556-66. PubMed ID: 21623212
[TBL] [Abstract][Full Text] [Related]
26. Intravenous lipid emulsion does not reverse dabigatran-induced anticoagulation in a rat model.
Blum J; Carreiro S; Hack JB
Acad Emerg Med; 2013 Oct; 20(10):1022-5. PubMed ID: 24127705
[TBL] [Abstract][Full Text] [Related]
27. [Dabigatran, a new oral anticoagulant].
Uchiyama S
Brain Nerve; 2011 Apr; 63(4):411-5. PubMed ID: 21441645
[TBL] [Abstract][Full Text] [Related]
28. Positive outcome after intentional overdose of dabigatran.
Woo JS; Kapadia N; Phanco SE; Lynch CA
J Med Toxicol; 2013 Jun; 9(2):192-5. PubMed ID: 23212788
[TBL] [Abstract][Full Text] [Related]
29. Safe use of hemodialysis for dabigatran removal before cardiac surgery.
Wanek MR; Horn ET; Elapavaluru S; Baroody SC; Sokos G
Ann Pharmacother; 2012 Sep; 46(9):e21. PubMed ID: 22872748
[TBL] [Abstract][Full Text] [Related]
30. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran.
Stangier J; Feuring M
Blood Coagul Fibrinolysis; 2012 Mar; 23(2):138-43. PubMed ID: 22227958
[TBL] [Abstract][Full Text] [Related]
31. Dabigatran in patients with nonvalvular atrial fibrillation.
Gage L
J Am Coll Cardiol; 2011 Jul; 58(5):551; author reply 551. PubMed ID: 21777759
[No Abstract] [Full Text] [Related]
32. Ischemic stroke in an obese patient receiving dabigatran.
Breuer L; Ringwald J; Schwab S; Köhrmann M
N Engl J Med; 2013 Jun; 368(25):2440-2. PubMed ID: 23782198
[No Abstract] [Full Text] [Related]
33. Population pharmacokinetics of telbivudine and determination of dose adjustment for patients with renal impairment.
Zhou XJ; Ke J; Sallas WM; Farrell C; Mayers DL; Pentikis HS
J Clin Pharmacol; 2009 Jun; 49(6):725-34. PubMed ID: 19395586
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics of maribavir, a novel oral anticytomegalovirus agent, in subjects with varying degrees of renal impairment.
Swan SK; Smith WB; Marbury TC; Schumacher M; Dougherty C; Mico BA; Villano SA
J Clin Pharmacol; 2007 Feb; 47(2):209-17. PubMed ID: 17244772
[TBL] [Abstract][Full Text] [Related]
35. Measuring dabigatran concentrations using a chromogenic ecarin clotting time assay.
Gosselin RC; Dwyre DM; Dager WE
Ann Pharmacother; 2013 Dec; 47(12):1635-40. PubMed ID: 24259624
[TBL] [Abstract][Full Text] [Related]
36. Thrombolysis treatment for acute ischaemic stroke in a patient on treatment with dabigatran.
Matute MC; Guillán M; García-Caldentey J; Buisan J; Aparicio M; Masjuan J; Alonso de Leciñana M
Thromb Haemost; 2011 Jul; 106(1):178-9. PubMed ID: 21505718
[No Abstract] [Full Text] [Related]
37. Drug-induced exanthem following dabigatran.
Whitehead H; Boyd JM; Blais DM; Hummel J
Ann Pharmacother; 2011 Oct; 45(10):e53. PubMed ID: 21881034
[TBL] [Abstract][Full Text] [Related]
38. Prophylaxis of venous thromboembolism: low molecular weight heparin compared to the selective anticoagulants rivaroxaban, dabigatran and fondaparinux.
Welzel D; Hull R; Fareed J
Int Angiol; 2011 Jun; 30(3):199-211. PubMed ID: 21617603
[TBL] [Abstract][Full Text] [Related]
39. Population pharmacokinetic analysis of oseltamivir and oseltamivir carboxylate following intravenous and oral administration to patients with and without renal impairment.
Gibiansky L; Giraudon M; Rayner CR; Brennan BJ; Subramoney V; Robson R; Kamal MA
J Pharmacokinet Pharmacodyn; 2015 Jun; 42(3):225-36. PubMed ID: 25821064
[TBL] [Abstract][Full Text] [Related]
40. Dabigatran: will it change clinical practice?
Wartak SA; Bartholomew JR
Cleve Clin J Med; 2011 Oct; 78(10):657-64. PubMed ID: 21968472
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
